Anti-Drug Antibodies May Affect RA Treatment

The researchers then examined patient-reported outcomes and, surprisingly, found no differences between serum trough drug concentration and those outcomes in patients treated with etanercept or infliximab. However, patients treated with adalimumab did have a statistically significant negative correlation between serum trough drug concentration and Health Assessment Questionnaire Disability Index. The investigators suggested that these finding may be a reflection of their study design, in which patients were recruited only if they were satisfied with their given treatment.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017.

The Americans with Disabilities Act (ADA) was passed in 1990 to protect the civil rights of people with disabilities. This law, and amendments passed in 2008, resulted in rules and regulations opening access to private settings serving the public, including doctors’ offices and medical facilities. The ADA includes a three-pronged definition of disability. If any…

Reckless approach versus missed opportunity?

Tracking the results of drug safety and efficacy

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Do You Know Your Legal Obligations to Disabled Patients?

TNF Blockade for SLE

Drug Updates: EULAR 2012

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Related Articles